Tempus
Tempus Strikes Cancer Drug Research Deal With JW Pharmaceutical
As part of the collaboration, the companies will use Tempus' biological modeling platform and collection of patient-derived cancer organoid models.
Avacta Therapeutics, Tempus Partner to Advance FAP-Based Peptide Drug Conjugates
Avacta will tap into Tempus' real-world data and machine-learning abilities to develop drugs with its fibroblast activation protein (FAP)-based platform.
The firm has submitted its xR assay to the FDA and is prioritizing its entry into the minimal residual disease space.
Tempus, Takeda Expand Collaboration to Use Multimodal Data for Oncology R&D
Takeda will use Tempus' multimodal datasets and biological modeling capabilities in its cancer therapeutic development work.
The test assigns a pancreatic cancer subtype based on the expression of 16 genes measured using an array.
Jul 19, 2024
New Products Posted to GenomeWeb: Tempus, MSAID
Jun 14, 2024
Guardant Health Sues Tempus for Patent Infringement
Jun 14, 2024
Tempus AI Prices $410.7M Initial Public Offering
May 21, 2024
Tempus AI Files for Initial Public Offering
Dec 6, 2023